title: [Use of ocular drugs in pregnancy].
abstract: The information available on the safety of medicines in pregnant women is limited and must be suitably channeled. Medication that is applied topically or as eye drops can present relevant systemic absorption and cross the placenta barrier or enter maternal milk. We have reviewed ophthalmic medicines according to the fetal risk categories proposed by the classification of the Food and Drug Administration (FDA). We evaluate the medicines of choice in the most frequent ophthalmic pathologies, as well as the medicines that must be avoided.
authors.affiliation: Servicio de Oftalmología A, Complejo Hospitalario de Navarra, Pamplona 31008, Spain. nataliaarruti@hotmail.com.
authors.forename: N
authors.initials: N
authors.lastname: Arruti
authors.forename: A
authors.initials: A
authors.lastname: Rebollo
authors.forename: G
authors.initials: G
authors.lastname: Mezquita
authors.forename: A
authors.initials: A
authors.lastname: Alcaine
authors.forename: J
authors.initials: J
authors.lastname: Andonegui
mesh_terms: D064420:Drug-Related Side Effects and Adverse Reactions; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D009883:Ophthalmic Solutions / Q000009:adverse effects*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*
chemical_list: D009883:Ophthalmic Solutions